about
Primary hepatic carcinoid tumoursGlaucarubinone and gemcitabine synergistically reduce pancreatic cancer growth via down-regulation of P21-activated kinasesInterstitial laser thermotherapy for liver tumours.Effect of interstitial laser hyperthermia in a murine model of colorectal liver metastases: scanning electron microscopic study.Focal hyperthermia produces progressive tumor necrosis independent of the initial thermal effects.Progressive microvascular injury in liver and colorectal liver metastases following laser induced focal hyperthermia therapy.Comparison of 980- and 1064-nm wavelengths for interstitial laser thermotherapy of the liver.Patterns of heat shock protein (HSP70) expression and Kupffer cell activity following thermal ablation of liver and colorectal liver metastases.Effect of thalidomide on colorectal cancer liver metastases in CBA mice.Mechanisms of focal heat destruction of liver tumors.Altered growth patterns of colorectal liver metastases after thermal ablation.Impact of blood flow occlusion on liver necrosis following thermal ablation.Feasibility of radiofrequency ablation for the treatment of chronic radiation proctitis.The impact of fluid intervention on complications and length of hospital stay after pancreaticoduodenectomy (Whipple's procedure)Depletion of p21-activated kinase 1 up-regulates the immune system of APC∆14/+ mice and inhibits intestinal tumorigenesis.Fluid prescription practices of anesthesiologists managing patients undergoing elective colonoscopy: an observational studyChanges in growth factor levels after thermal ablation in a murine model of colorectal liver metastasesSpatial morphological and molecular differences within solid tumors may contribute to the failure of vascular disruptive agent treatments.Association of diabetes mellitus and pancreatic adenocarcinoma: a meta-analysis of 88 studies.FRAX597, a PAK1 inhibitor, synergistically reduces pancreatic cancer growth when combined with gemcitabine.Reduction of surgical site infections by use of pulsatile lavage irrigation after prolonged intra-abdominal surgical procedures.Combined pancreaticoduodenectomy and extended right hemicolectomy: outcomes and indications.Treatment with the vascular disruptive agent OXi4503 induces an immediate and widespread epithelial to mesenchymal transition in the surviving tumor.Outcomes of patients with histologically proven acute acalculous cholecystitis.Sex differences and outcomes of management of acute cholecystitis.Lymphatics and colorectal liver metastases: the case for sentinel node mapping.K-Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines.Summary and recommendations from the Australasian guidelines for the management of pancreatic exocrine insufficiency.Refining the care of patients with pancreatic cancer: the AGITG Pancreatic Cancer Workshop consensus.Assessment of Liver Remnant Using ICG Clearance Intraoperatively during Vascular Exclusion: Early Experience with the ALIIVE TechniqueComparison of two syngeneic orthotopic murine models of pancreatic adenocarcinoma.The outcomes of pancreaticoduodenectomy in patients aged 80 or older: a systematic review and meta-analysis.In vitro and in vivo evaluation of tumor targeting styrene-maleic acid copolymer-pirarubicin micelles: Survival improvement and inhibition of liver metastases.Lymphatic patterns of colorectal liver metastases.Vascular targeting agent Oxi4503 inhibits tumor growth in a colorectal liver metastases model.Liver regeneration stimulates tumor metastases.Restrictive intraoperative fluid optimisation algorithm improves outcomes in patients undergoing pancreaticoduodenectomy: A prospective multicentre randomized controlled trial.Postoperative wristwatch-induced compressive neuropathy of the hand: a case report.Pylorus preserving pancreaticoduodenectomy.Outcomes of cholecystectomy for treatment of acute cholecystitis in octogenarians.
P50
Q28272261-63CED7D7-E725-4A02-AFC4-D5D0921D397DQ28307180-DDCFE119-2976-4F52-94D7-998B9DE1113DQ31155171-6365673B-FB09-4434-8C5A-044F6DB9B87BQ33195492-CE81A88A-B7EA-4F73-8446-82E6FEDDC9F5Q33212569-052D6ACF-1B86-48FC-80A2-F391D9C2E360Q33217046-E7F28DA3-04F1-4749-A9AF-47F415B7CC15Q33217080-E33AA92E-CE62-4B6C-985A-94517DDEE134Q33219522-23434990-7C17-4F3E-AEB4-A3F82057D25FQ33219853-CDA2FAB6-D4C4-47CA-860B-5E4018550BD1Q33221211-4484A661-9C5E-40CD-9E5D-2D987F8A09F0Q33229907-0C225DFB-3CA2-4FF0-9294-2A060A818F4FQ33234134-B704424F-AB54-485F-9252-6E9B29BDC6C8Q33588333-0B7465A5-4D14-43A7-B573-D4C7E986C26DQ33623773-66DE7C03-AD40-4225-AC68-EFA14CA9F5F4Q33814329-DB87C2D6-F265-435A-9BB7-B90349609907Q33830605-12E82086-5BD5-4D81-8529-A3F3CA90A2B7Q33850209-16E1823A-E23A-4C87-AB98-89B2C71728FAQ34478450-04D7D597-12EF-49DE-9F6C-26AA0E73182EQ34660246-BC38C37D-D5EF-433C-8E98-3C14DD8CFB28Q35895894-B7BB71B2-0932-4A97-A3E9-D1A6295D8C85Q37432629-6D496C92-616C-43F9-B4D9-B043C5350AAFQ37449347-1CF3E7DA-38ED-4343-B201-B9AB967F086EQ37482536-146C8BD8-7714-47C1-B9C9-C2162B4DBED6Q38040173-3EDF83FA-4815-44A3-B352-DCC7F5E40445Q38079535-E4CAB623-53B6-4069-947D-71D7E98A2A95Q38122755-AF20E893-BF03-4184-8859-F54C6184D6C4Q38678966-ED0230FD-4B51-41FD-B924-FB714636FE8CQ38699373-45328CF2-7243-40FB-A8C4-EC5085C4E385Q38869289-A576A425-447B-4C7A-8A50-78CE9B473D65Q38992142-0FD9EF94-D4CC-41CC-A2FD-06A6FFF56568Q39108406-74F0AA82-10FA-4F20-9D15-9DF0CCD7425EQ39178239-605752AB-E1FD-402E-8D6A-A56062B407B0Q39688233-68207609-1AD0-4317-B0B0-D2D96A86ABB8Q39956954-99C3BAAF-0416-46B3-8466-E393BC9B1FD6Q40121939-8C578CC2-F0B4-4672-961C-7EFBADE1CF76Q40179022-04202078-A78D-44FF-B906-52C0001E8FF5Q41576758-4BD5BAD9-08DE-46BA-9616-BC0EB1CB3704Q42424482-EB1906FD-413B-4581-B0B1-8B2469DA7A01Q42562909-D1B5D636-71F1-4B6D-9A2A-EAA02341A737Q42611882-04DB8CB7-2A9D-45FA-8D91-5AEF40FA3CE2
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Mehrdad Nikfarjam
@ast
Mehrdad Nikfarjam
@en
Mehrdad Nikfarjam
@es
Mehrdad Nikfarjam
@sl
type
label
Mehrdad Nikfarjam
@ast
Mehrdad Nikfarjam
@en
Mehrdad Nikfarjam
@es
Mehrdad Nikfarjam
@sl
prefLabel
Mehrdad Nikfarjam
@ast
Mehrdad Nikfarjam
@en
Mehrdad Nikfarjam
@es
Mehrdad Nikfarjam
@sl
P106
P1153
6602131170
P21
P31
P496
0000-0003-4866-276X
P569
2000-01-01T00:00:00Z